Copyright Reports & Markets. All rights reserved.

Europe Inhalers for Chronic Obstructive Pulmonary Disorder Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Inhalers for Chronic Obstructive Pulmonary Disorder Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Metered-Dose Inhalers (MDI's) Market Performance (Volume)
      • 2.1.2 Dry Powder Inhalers (DPI's) Market Performance (Volume)
      • 2.1.3 Soft Mist Inhalers (SMI's) Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Metered-Dose Inhalers (MDI's) Market Performance (Value)
      • 2.1.2 Dry Powder Inhalers (DPI's) Market Performance (Value)
      • 2.1.3 Soft Mist Inhalers (SMI's) Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 GOLD 1： FEV1 ≥ 80% Market Performance (Volume)
      • 3.1.2 GOLD 2： 50% ≤ FEV1 < 80% Market Performance (Volume)
      • 3.1.3 GOLD 3： 30% ≤ FEV1 < 50% Market Performance (Volume)
      • 3.1.4 GOLD 4： FEV1 < 30% Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 AstraZeneca
      • 4.1.1 AstraZeneca Profiles
      • 4.1.2 AstraZeneca Product Information
      • 4.1.3 AstraZeneca Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
      • 4.1.4 AstraZeneca Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
    • 4.2 Boehringer Ingelheim
      • 4.2.1 Boehringer Ingelheim Profiles
      • 4.2.2 Boehringer Ingelheim Product Information
      • 4.2.3 Boehringer Ingelheim Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
      • 4.2.4 Boehringer Ingelheim Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
    • 4.3 GSK
      • 4.3.1 GSK Profiles
      • 4.3.2 GSK Product Information
      • 4.3.3 GSK Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
      • 4.3.4 GSK Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
    • 4.4 Novartis
      • 4.4.1 Novartis Profiles
      • 4.4.2 Novartis Product Information
      • 4.4.3 Novartis Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
      • 4.4.4 Novartis Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
    • 4.5 Teva Pharmaceuticals
      • 4.5.1 Teva Pharmaceuticals Profiles
      • 4.5.2 Teva Pharmaceuticals Product Information
      • 4.5.3 Teva Pharmaceuticals Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
      • 4.5.4 Teva Pharmaceuticals Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
    • 4.6 Ache Laboratorios Farmaceuticos
      • 4.6.1 Ache Laboratorios Farmaceuticos Profiles
      • 4.6.2 Ache Laboratorios Farmaceuticos Product Information
      • 4.6.3 Ache Laboratorios Farmaceuticos Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
      • 4.6.4 Ache Laboratorios Farmaceuticos Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
    • 4.7 Almirall
      • 4.7.1 Almirall Profiles
      • 4.7.2 Almirall Product Information
      • 4.7.3 Almirall Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
      • 4.7.4 Almirall Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
    • 4.8 Aquinox Pharmaceuticals
      • 4.8.1 Aquinox Pharmaceuticals Profiles
      • 4.8.2 Aquinox Pharmaceuticals Product Information
      • 4.8.3 Aquinox Pharmaceuticals Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
      • 4.8.4 Aquinox Pharmaceuticals Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
    • 4.9 Ario Pharma
      • 4.9.1 Ario Pharma Profiles
      • 4.9.2 Ario Pharma Product Information
      • 4.9.3 Ario Pharma Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
      • 4.9.4 Ario Pharma Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
    • 4.10 Asmacure
      • 4.10.1 Asmacure Profiles
      • 4.10.2 Asmacure Product Information
      • 4.10.3 Asmacure Inhalers for Chronic Obstructive Pulmonary Disorder Business Performance
      • 4.10.4 Asmacure Inhalers for Chronic Obstructive Pulmonary Disorder Business Development and Market Status
    • 4.11 Astellas Pharma
    • 4.12 BioMarck Pharmaceuticals
    • 4.13 GSK

    5 Market Performance for Manufacturers

    • 5.1 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 Germany Market Performance for Manufacturers
      • 6.1.1 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 UK Market Performance for Manufacturers
      • 6.2.1 UK Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 UK Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 UK Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 UK Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 France Market Performance for Manufacturers
      • 6.3.1 France Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 France Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 France Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 France Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Russia Market Performance for Manufacturers
      • 6.4.1 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 Benelux Market Performance for Manufacturers
      • 6.5.1 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 Italy Market Performance for Manufacturers
      • 6.6.1 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Spain Market Performance for Manufacturers
      • 6.7.1 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.8.2 Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.8.3 Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) of Manufacturers 2013-2018
      • 6.8.4 Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin of Manufacturers 2013-2018
      • 6.8.5 Market Concentration

    7 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Market Performance (Sales Point)

    • 7.1 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) by Regions 2013-2018
    • 7.4 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 UK Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 France Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 GOLD 1： FEV1 ≥ 80% Industry
    • 11.2 GOLD 2： 50% ≤ FEV1 < 80% Industry
    • 11.3 GOLD 3： 30% ≤ FEV1 < 50% Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 Germany Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 UK Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 France Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Russia Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 Benelux Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Italy Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Spain Inhalers for Chronic Obstructive Pulmonary Disorder Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Metered-Dose Inhalers (MDI's) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Dry Powder Inhalers (DPI's) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 Soft Mist Inhalers (SMI's) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 GOLD 1： FEV1 ≥ 80% Sales and and Growth Rate 2019-2024
      • 12.4.3 GOLD 2： 50% ≤ FEV1 < 80% Sales and and Growth Rate 2019-2024
      • 12.4.4 GOLD 3： 30% ≤ FEV1 < 50% Sales and and Growth Rate 2019-2024
      • 12.4.5 GOLD 4： FEV1 < 30% Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Price (USD/Unit) Trend 2019-2024
      • 12.5.2 Europe Inhalers for Chronic Obstructive Pulmonary Disorder Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Inhalers for Chronic Obstructive Pulmonary Disorder for these regions, from 2012 to 2023 (forecast), including
    Germany
    UK
    France
    Russia
    Benelux
    Italy
    Spain

    Europe Inhalers for Chronic Obstructive Pulmonary Disorder market competition by top manufacturers/players, with Inhalers for Chronic Obstructive Pulmonary Disorder sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    AstraZeneca
    Boehringer Ingelheim
    GSK
    Novartis
    Teva Pharmaceuticals
    Ache Laboratorios Farmaceuticos
    Almirall
    Aquinox Pharmaceuticals
    Ario Pharma
    Asmacure
    Astellas Pharma
    BioMarck Pharmaceuticals
    Others

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Metered-Dose Inhalers (MDI's)
    Dry Powder Inhalers (DPI's)
    Soft Mist Inhalers (SMI's)

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Inhalers for Chronic Obstructive Pulmonary Disorder for each application, including
    GOLD 1： FEV1 ≥ 80%
    GOLD 2： 50% ≤ FEV1 < 80%
    GOLD 3： 30% ≤ FEV1 < 50%
    GOLD 4： FEV1 < 30%

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now